Early CPAP versus Surfactant in Extremely Preterm Infants

SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network*

ABSTRACT

BACKGROUND
There are limited data to inform the choice between early treatment with continuous positive airway pressure (CPAP) and early surfactant treatment as the initial support for extremely-low-birth-weight infants.

METHODS
We performed a randomized, multicenter trial, with a 2-by-2 factorial design, involving infants who were born between 24 weeks 0 days and 27 weeks 6 days of gestation. Infants were randomly assigned to intubation and surfactant treatment (within 1 hour after birth) or to CPAP treatment initiated in the delivery room, with subsequent use of a protocol-driven limited ventilation strategy. Infants were also randomly assigned to one of two target ranges of oxygen saturation. The primary outcome was death or bronchopulmonary dysplasia as defined by the requirement for supplemental oxygen at 36 weeks (with an attempt at withdrawal of supplemental oxygen in neonates who were receiving less than 30% oxygen).

RESULTS
A total of 1316 infants were enrolled in the study. The rates of the primary outcome did not differ significantly between the CPAP group and the surfactant group (47.8% and 51.0%, respectively; relative risk with CPAP, 0.95; 95% confidence interval [CI], 0.85 to 1.05) after adjustment for gestational age, center, and familial clustering. The results were similar when bronchopulmonary dysplasia was defined according to the need for any supplemental oxygen at 36 weeks (rates of primary outcome, 48.7% and 54.1%, respectively; relative risk with CPAP, 0.91; 95% CI, 0.83 to 1.01). Infants who received CPAP treatment, as compared with infants who received surfactant treatment, less frequently required intubation or postnatal corticosteroids for bronchopulmonary dysplasia (P<0.001), required fewer days of mechanical ventilation (P=0.03), and were more likely to be alive and free from the need for mechanical ventilation by day 7 (P=0.01). The rates of other adverse neonatal outcomes did not differ significantly between the two groups.

CONCLUSIONS
The results of this study support consideration of CPAP as an alternative to intubation and surfactant in preterm infants. (ClinicalTrials.gov number, NCT00233324.)
IT HAS BEEN SHOWN THAT SURFACTANT treatment at less than 2 hours of life significantly decreases the rates of death, air leak, and death or bronchopulmonary dysplasia in preterm infants. Overall, prophylactic treatment with surfactant has not been shown to significantly reduce the risk of bronchopulmonary dysplasia alone, whereas studies comparing early with later rescue use of surfactant have shown that there is a decreased risk of chronic lung disease with early use. Several studies have shown that the use of surfactant does not have a significant effect on the risk of subsequent neurodevelopmental impairment, although a recent follow-up assessment of infants involved in a randomized trial showed that early surfactant treatment (at a mean of 31 minutes of age) as compared with later surfactant treatment (at a mean of 202 minutes of age) was associated with a significantly higher rate of increased muscle tone in the infants and a delay in the infants’ ability to roll from the supine to the prone position. However, in many of the trials of surfactant treatment, the rate of maternal corticosteroid therapy before delivery — an intervention known to improve neonatal survival and decrease the rate of complications — was not high, and none of the infants in the control group received early treatment with continuous positive airway pressure (CPAP). There is a growing body of observational evidence suggesting that in the case of very preterm infants with respiratory distress who are not treated initially with surfactant, the early use of CPAP may decrease the need for mechanical ventilation without an increase in complications.

In a previous study reported in the *Journal*, 610 infants, born between 25 weeks and 28 weeks 6 days of gestation, who were able to breathe at 5 minutes of age and had evidence of respiratory distress at that time, were randomly assigned to either intubation and ventilation or CPAP at a pressure of 8 cm of water; infants who were randomly assigned to CPAP were intubated if they met certain criteria for the failure of CPAP treatment. There was no significant reduction in the CPAP group, as compared with the intubated group, in the rate of death or the need for supplemental oxygen at 36 weeks (the primary outcome), and there was a significantly higher rate of pneumothorax in the CPAP group than in the intubated group (9.1% vs. 3.0%); most of the cases of pneumothorax occurred within the first 2 days, which is consistent with the findings of a previous meta-analysis.

We designed the Surfactant, Positive Pressure, and Oxygenation Randomized Trial (SUPPORT) to compare early CPAP treatment with early surfactant treatment in extremely preterm infants. Using a factorial design, we also randomly assigned infants to one of two target ranges of oxygen saturation during their exposure to supplemental oxygen.

**Methods**

In this randomized, multicenter trial, we compared a strategy of treatment with CPAP and protocol-driven limited ventilation begun in the delivery room and continued in the neonatal intensive care unit (NICU) with a strategy of early intratracheal administration of surfactant (within 1 hour after birth) followed by a conventional ventilation strategy. In a 2-by-2 factorial design, infants were also randomly assigned to one of two target ranges of oxygen saturation (85 to 89% or 91 to 95%) until the infant was 36 weeks of age or no longer received ventilatory support or supplemental oxygen. The results of this portion of the study are discussed elsewhere in this issue of the *Journal*. Randomization was stratified according to center and gestational-age group, with the use of specially prepared double-sealed envelopes, and was performed before the actual delivery. Infants who were part of multiple births were randomly assigned to the same group. Written informed consent from a parent or guardian for an infant’s participation in the trial was required before delivery.

Infants were eligible for inclusion in the study if they were 24 weeks 0 days to 27 weeks 6 days of gestation at birth according to the best obstetrical estimate, if they were born without known malformations at a participating center, if a decision had been made to provide full resuscitation for them, and if written informed consent had been obtained from a parent or guardian. The infants were randomly assigned within each center and within each gestational-age stratum (24 weeks 0 days to 25 weeks 6 days or 26 weeks 0 days to 27 weeks 6 days).

The study was conducted as part of the Neonatal Research Network of the Eunice Kennedy
In the delivery room, CPAP was administered by means of a T-piece resuscitator, a neonatal ventilator, or an equivalent device. CPAP or ventilation with positive end-expiratory pressure (PEEP) (at a recommended pressure of 5 cm of water) was used if the infant received positive-pressure ventilation during resuscitation. CPAP was continued until the infant's admission to the NICU. Intubation was not performed for the sole purpose of surfactant administration in infants who were randomly assigned to the CPAP group, but infants who required intubation for resuscitation on the basis of standard indications specified in the Neonatal Resuscitation Program guidelines15 were given surfactant within 60 minutes after birth.

In the NICU, infants who were randomly assigned to CPAP could be intubated if they met any of the following criteria: a fraction of inspired oxygen (FiO2) greater than 0.50 required to maintain an indicated saturation of peripheral oxygen (SpO2) at or above 88% for 1 hour; a partial pressure of arterial carbon dioxide (PaCO2) greater than 65 mm Hg, documented by a single measurement of blood gases within 1 hour before intubation; or hemodynamic instability, defined as a blood pressure that was low for gestational age, poor perfusion, or both, requiring volume or pressor support for a period of 4 hours or more. Infants who were intubated within the first 48 hours after birth were to receive surfactant. After an infant's admission to the NICU, the unit used its standard method for the delivery of CPAP — that is, a ventilator, a purpose-built flow driver, or a bubble CPAP circuit.

Extubation of an infant in the CPAP group was to be attempted within 24 hours after the infant met all of the following criteria: a PaCO2 below 65 mm Hg with a pH higher than 7.20, an SpO2 above 88% with an FiO2 below 0.50, a mean airway pressure of less than 10 cm of water, a ventilator rate of less than 20 breaths per minute, an amplitude of less than twice the mean airway pressure if high-frequency ventilation was being used, hemodynamic stability, and the absence of clinically significant patent ductus arteriosus. Criteria for reintubation were the same as those for initial intubation. After three intubations, infants in the CPAP group received treatment according to the standard practice in the NICU to which they had been admitted.

SURFACTANT GROUP
All the infants in the surfactant group were to be intubated in the delivery room and were to receive surfactant within 1 hour after birth with continued ventilation thereafter. The infants were to be extubated within 24 hours after meeting all of the following criteria: a PaCO2 of less than 50 mm Hg and a pH higher than 7.30, an FiO2 of 0.35 or less with an SpO2 of 88% or higher, a mean airway pressure of 8 cm of water or less, a ventilator rate of 20 breaths per minute or less, an amplitude of less than twice the mean airway pressure if high-frequency ventilation was being used, and hemodynamic stability without evidence of clinically significant patent ductus arteriosus. Once the infants were extubated, they were treated according to the standard practice in the NICU to which they had been admitted.

The criteria for both groups were in effect for the infants' first 14 days of life, after which the infants were treated according to the standard practice in the NICU to which they had been admitted. In the case of both groups, intubation could be performed at any time if there was an episode of repetitive apnea requiring bag-and-mask ventilation, clinical shock, or sepsis, or if surgery was required.

OUTCOMES
The primary outcome was death or bronchopulmonary dysplasia. Bronchopulmonary dysplasia was defined according to the physiological definition, as the receipt of more than 30% supplemental oxygen at 36 weeks or the need for positive-pressure support or, in the case of infants requiring less than 30% oxygen, the need for any supplemental oxygen at 36 weeks after an attempt at withdrawal of oxygen.16,17 Prespecified secondary outcomes included bronchopulmonary dysplasia as defined by the receipt of any supplemental oxygen at 36 weeks. Prespecified safety
outcomes included death, pneumothorax, intraventricular hemorrhage, and the need for chest compressions or epinephrine during resuscitation.

**STATISTICAL ANALYSIS**

The sample-size calculations were based on data from the Neonatal Research Network from the year 2000, which showed that the rate of death or survival with bronchopulmonary dysplasia at 36 weeks was 67% and the rate of death or survival with neurodevelopmental impairment at 18 to 22 months was 61%. We hypothesized that with early CPAP there would be a reduction of 10% in the incidence of these complications. We increased the sample size by a factor of 1.12 to allow for infants in multiple births to be randomly assigned to the same treatment, because this introduced a clustering effect into the design, and we increased the sample sizes by an additional 17% to adjust for loss to follow-up after discharge. We increased the sample size further to minimize type I error with the use of a conservative 2% level of significance. The result was a target sample of 1310 infants. We planned to test for an interaction between the two factorial parts of the study, but the study was not powered for that analysis.

Analyses were performed according to the intention-to-treat principle. The denominator that was used to calculate the rate of each outcome was the number of infants for whom that outcome was known. The primary analyses focused on the percentage of infants in each group who survived to 36 weeks of postmenstrual age without bronchopulmonary dysplasia. Analysis of this and all other categorical outcomes was performed with the use of robust Poisson regression in a generalized-estimating-equation model to obtain adjusted relative risks with 95% confidence intervals. Continuous outcomes were analyzed with the use of mixed-effects linear models to obtain adjusted means and standard errors.

In the analysis of all outcomes, the results were adjusted, as prespecified, for gestational-age strata, center, and familial clustering. Two-sided P values of less than 0.05 were considered to indicate statistical significance, and no adjustments have been made for multiple comparisons. An independent data and safety monitoring committee reviewed the interim safety and efficacy results — including those related to adverse outcomes — four times. Lan–DeMets spending functions with Po-cock and O’Brien–Fleming boundaries were used to determine stopping rules for interim safety and efficacy monitoring, respectively.

For the 46 planned analyses of secondary outcomes according to treatment, we would expect no more than 3 tests to have P values of less than 0.05 on the basis of chance alone. Subgroup analyses were conducted within prespecified gestational-age strata for 36 predefined outcomes. Although these tests have not been adjusted for multiple comparisons, we would expect no more than 2 tests per stratum to have P values of less than 0.05 on the basis of chance alone.

**RESULTS**

**CHARACTERISTICS OF THE STUDY SAMPLE**

From February 2005 through February 2009, a total of 1316 infants were enrolled, of whom 565 were in the lower gestational-age stratum (24 weeks 0 days to 25 weeks 6 days) and 751 were in the higher stratum (26 weeks 0 days to 27 weeks 6 days) (Fig. 1). There were no significant differences between the two treatment groups with respect to sex, birth weight, or race or ethnic group (Table 1).

Delivery room interventions in the two groups are summarized in Table 2. The rates of intubation in the delivery room and of the use of positive-pressure ventilation or epinephrine to treat persistent bradycardia were significantly lower among infants randomly assigned to CPAP than among those assigned to surfactant treatment. Overall, 32.9% of the infants in the CPAP group did not receive surfactant during their hospitalization.

**PRIMARY OUTCOME**

After adjustment for gestational age, center, and familial clustering, the rates of the primary outcome of death or bronchopulmonary dysplasia as assessed according to the physiological definition did not differ significantly between the two groups. The results were similar when bronchopulmonary dysplasia was defined according to the need for any supplemental oxygen at 36 weeks. When components of this composite outcome were analyzed separately, there was no significant between-group difference in the rate of death or the rate of bronchopulmonary dysplasia (Table 3).
3546 Infants were assessed for eligibility (3127 pregnancies)

2230 Were excluded
235 Did not meet eligibility criteria
125 Did not have personnel or equipment available
699 Were eligible, but consent was not sought
344 Were excluded because parent or guardian was unavailable
748 Had consent denied by parent or guardian
11 Had other reasons
68 Had consent provided but did not undergo randomization

1316 Underwent randomization

654 Were assigned to target oxygen saturation of 85–89%

336 Were assigned to receive early CPAP
54 Died
282 Survived to 36 wk postmenstrual age
103 Had BPD
179 Did not have BPD

318 Were assigned to receive early surfactant
60 Died
258 Survived to 36 wk postmenstrual age
102 Had BPD
156 Did not have BPD

662 Were assigned to target oxygen saturation of 91–95%

327 Were assigned to receive early CPAP
40 Died
287 Survived to 36 wk postmenstrual age
120 Had BPD
167 Did not have BPD

335 Were assigned to receive early surfactant
54 Died
281 Survived to 36 wk postmenstrual age
117 Had BPD
164 Did not have BPD
There was no significant interaction between the two interventions assessed in the trial with respect to the primary outcome of death or bronchopulmonary dysplasia as assessed either according to the physiological definition (P = 0.59) or according to the need for any supplemental oxygen at 36 weeks (P = 0.53). There was no significant interaction between gestational-age stratum and treatment strategy with respect to the primary outcome (P = 0.84 with the physiological definition of bronchopulmonary dysplasia and P = 0.44 with bronchopulmonary dysplasia defined according to the need for any supplemental oxygen at 36 weeks), and there was no significant between-group difference in the rate of the primary outcome (with either definition of bronchopulmonary dysplasia) in either gestational-age stratum.

**SECONDARY OUTCOMES**

More infants in the CPAP group than in the surfactant group were alive and free from the need for mechanical ventilation by day 7 (P = 0.01), and more infants in the CPAP group were intubated (P < 0.001) (Table 3). The other secondary outcomes are shown in Table 3.

In post hoc stratified analyses of secondary outcomes, among infants who were born between 24 weeks 0 days and 25 weeks 6 days of gestation, the rates of death during hospitalization and at 36 weeks were significantly lower in the CPAP group than in the surfactant group (P < 0.001) (Table 3). The other secondary outcomes are shown in Table 3.

was not intubated; 83.1% of the infants in the CPAP group were intubated (P < 0.001). The rate of use of postnatal corticosteroids to treat bronchopulmonary dysplasia was lower in the CPAP group than in the surfactant group (P < 0.001) (Table 3). The other secondary outcomes are shown in Table 3.
In this multicenter, randomized trial involving extremely preterm infants, there was no significant difference between a strategy of early CPAP and limited ventilation and a strategy of early intubation and surfactant administration within 1 hour after birth with respect to the rate of the composite primary outcome of death or bronchopulmonary dysplasia. We used the physiological definition of bronchopulmonary dysplasia, since it includes as a specification an attempt to withdraw supplemental oxygen from infants receiving less than 30% oxygen at 36 weeks, in order to confirm their need for supplemental oxygen.\(^{16,17}\) Plausible results, on the basis of the 95% confidence intervals for the relative-risk estimates, included a risk of death or bronchopulmonary dysplasia in the CPAP group that was between 85 and 105% of that in the surfactant group. The results were similar in secondary analyses in which bronchopulmonary dysplasia was defined according to the use of any supplemental oxygen at 36 weeks.

We did not include infants who were born at a gestational age of less than 24 weeks, since the results of a pilot trial showed that 100% of such infants required intubation in the delivery room.\(^{19}\) A retrospective study showed that some infants in this gestational-age group can be treated successfully with early CPAP, but the majority require intubation.\(^{20}\)

There was a high rate of intubation and surfactant treatment among infants assigned to CPAP, but this was anticipated, given the design of the study, which was to test an initial strategy of early CPAP as compared with early intubation and surfactant, with crossover planned for ethical reasons in the case of infants in whom CPAP treatment was not successful. Our trial differs from the trial of Morley et al.\(^{12}\) in that we randomly assigned all eligible preterm infants to a treatment group, irrespective of whether they were breathing spontaneously or whether they had respiratory distress that warranted intervention, and in that we included infants who were born as early

---

**Table 2. Apgar Scores of Newborns and Interventions in the Delivery Room and NICU.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>CPAP (N=663)</th>
<th>Surfactant (N=653)</th>
<th>Relative Risk with CPAP (95% CI)</th>
<th>Adjusted P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>no./total no. (%)</td>
<td>no./total no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apgar score &lt;3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 1 min</td>
<td>154/661 (23.3)</td>
<td>167/653 (25.6)</td>
<td>0.92 (0.76–1.11)</td>
<td>0.38</td>
</tr>
<tr>
<td>At 5 min</td>
<td>26/663 (3.9)</td>
<td>32/653 (4.9)</td>
<td>0.82 (0.5–1.34)</td>
<td>0.43</td>
</tr>
<tr>
<td>PPV in the delivery room</td>
<td>435/662 (65.7)</td>
<td>606/652 (92.9)</td>
<td>0.71 (0.67–0.75)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CPAP in the delivery room</td>
<td>538/663 (81.1)</td>
<td>146/653 (22.4)</td>
<td>3.66 (3.16–4.25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intubation in the delivery room</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For any reason</td>
<td>227/660 (34.4)</td>
<td>609/652 (93.4)</td>
<td>0.37 (0.34–0.42)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>For resuscitation</td>
<td>215/660 (32.6)</td>
<td>176/652 (27.0)</td>
<td>1.21 (1.02–1.43)</td>
<td>0.02</td>
</tr>
<tr>
<td>Surfactant treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the delivery room</td>
<td>93/660 (14.1)</td>
<td>335/652 (51.4)</td>
<td>0.28 (0.23–0.34)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>In the delivery room or NICU</td>
<td>443/660 (67.1)</td>
<td>646/653 (98.9)</td>
<td>0.67 (0.64–0.71)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chest compressions in the delivery</td>
<td>36/660 (5.5)</td>
<td>40/653 (6.1)</td>
<td>0.86 (0.57–1.31)</td>
<td>0.48</td>
</tr>
<tr>
<td>room</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epinephrine in the delivery room</td>
<td>13/660 (2.0)</td>
<td>27/653 (4.1)</td>
<td>0.48 (0.25–0.91)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

* CI denotes confidence interval, CPAP continuous positive airway pressure, NICU neonatal intensive care unit, and PPV positive-pressure ventilation.
Early CPAP vs. Surfactant and Outcomes of Prematurity

Table 3. Selected Prespecified Outcomes,*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>CPAP (N = 663)</th>
<th>Surfactant (N = 653)</th>
<th>Relative Risk with CPAP (95% CI)</th>
<th>Difference in Means (95% CI)</th>
<th>Adjusted P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPD or death by 36 wk of postmenstrual age — no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiological definition of BPD†</td>
<td>317 (47.8)</td>
<td>333 (51.0)</td>
<td>0.95 (0.85 to 1.05)</td>
<td></td>
<td>0.30</td>
</tr>
<tr>
<td>BPD defined by need for supplemental oxygen</td>
<td>323 (48.7)</td>
<td>353 (54.1)</td>
<td>0.91 (0.83 to 1.01)</td>
<td></td>
<td>0.07</td>
</tr>
<tr>
<td>BPD by 36 wk of postmenstrual age — no./total no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiological definition of BPD†</td>
<td>223/569 (39.2)</td>
<td>219/539 (40.6)</td>
<td>0.99 (0.87 to 1.14)</td>
<td></td>
<td>0.92</td>
</tr>
<tr>
<td>BPD defined by need for supplemental oxygen</td>
<td>229/569 (40.2)</td>
<td>239/539 (44.3)</td>
<td>0.94 (0.82 to 1.06)</td>
<td></td>
<td>0.32</td>
</tr>
<tr>
<td>Death by 36 wk of postmenstrual age — no. (%)</td>
<td>94 (14.2)</td>
<td>114 (17.5)</td>
<td>0.81 (0.63 to 1.03)</td>
<td></td>
<td>0.09</td>
</tr>
<tr>
<td>Need for supplemental oxygen — no. of days‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Adjusted mean</td>
<td>62.2±1.6</td>
<td>65.3±1.6</td>
<td>−3.1 (−7.1 to 0.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted median</td>
<td>52</td>
<td>56</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interquartile range</td>
<td>20 to 86</td>
<td>27 to 91</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Need for mechanical ventilation — no. of days‡§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>Adjusted mean</td>
<td>24.8±1.0</td>
<td>27.7±1.1</td>
<td>−3.0 (−5.6 to −0.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted median</td>
<td>10</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interquartile range</td>
<td>2 to 32</td>
<td>2 to 36</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival without need for high-frequency or conventional ventilation at 7 days — no./total no. (%)</td>
<td>362/655 (55.3)</td>
<td>318/652 (48.8)</td>
<td>1.14 (1.03 to 1.25)</td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>Any air leak in first 14 days — no. (%)</td>
<td>45 (6.8)</td>
<td>48 (7.4)</td>
<td>0.89 (0.6 to 1.32)</td>
<td></td>
<td>0.56</td>
</tr>
<tr>
<td>Necrotizing enterocolitis requiring medical or surgical treatment — no./total no. (%)</td>
<td>83/654 (12.7)</td>
<td>63/636 (9.9)</td>
<td>1.25 (0.92 to 1.71)</td>
<td></td>
<td>0.15</td>
</tr>
<tr>
<td>Intraventricular hemorrhage grade 3 or 4 — no./total no. (%)‡¶</td>
<td>92/642 (14.3)</td>
<td>72/628 (11.5)</td>
<td>1.26 (0.94 to 1.68)</td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Postnatal corticosteroid therapy for BPD — no./total no. (%)</td>
<td>47/649 (7.2)</td>
<td>83/631 (13.2)</td>
<td>0.57 (0.41 to 0.78)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Severe retinopathy of prematurity among survivors — no./total no. (%)</td>
<td>67/511 (13.1)</td>
<td>65/473 (13.7)</td>
<td>0.94 (0.69 to 1.28)</td>
<td></td>
<td>0.71</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. BPD denotes bronchopulmonary dysplasia, CI confidence interval, and CPAP continuous positive airway pressure.
† The physiological definition of BPD includes, as a criterion, the receipt of more than 30% supplemental oxygen at 36 weeks, the need for positive-pressure support, or in the case of infants requiring less than 30% oxygen, the need for any supplemental oxygen at 36 weeks after an attempt at withdrawal of supplemental oxygen.16,17
‡ Data are for 1098 infants who survived to discharge, transfer, or 120 days; the maximum follow-up was 120 days.
§ This variable includes high-frequency ventilation and conventional ventilation.
¶ There are four grades of intraventricular hemorrhage; higher grades indicate more severe bleeding.

as 24 weeks of gestation. In the study by Morley et al., surfactant was not administered routinely in the intubation group. Our protocol, which called for early CPAP and a determination of the need for intubation, was based on the findings of previous observational studies showing that Neonatal Research Network sites that had the most experience with CPAP also used a higher threshold for intubation and the initiation of mechanical ventilation than did sites with less experience.4–6 The infants who were randomly assigned to surfactant treatment in our trial were
treated with a ventilation approach that was used by a majority of the Neonatal Research Network sites before the trial began. We believed that comparing these two methods would provide more clinically relevant results. Data are currently being collected to assess survival without neurodevelopmental impairment at 18 to 22 months.

We found no significant between-group differences in the rates of pneumothorax, intraventricular hemorrhage, or the need for chest compressions or epinephrine in the delivery room, and the rates were similar to those among infants in the Neonatal Research Network population who were born between 2000 and 2004 at similar gestational ages. The rate of air leaks in the first 14 days of life was not increased with the use of early CPAP at a pressure of 5 cm of water, as compared with the use of early surfactant.

In secondary analyses stratified according to gestational age at birth, there was a significant reduction in the risk of death in the CPAP group, as compared with the early-intubation group, among infants born between 24 weeks 0 days and 25 weeks 6 days of gestation but not among infants who were born at a later gestational age. Given the fact that there was no significant interaction between the intervention and gestational age, the post hoc nature of these analyses, and the number of secondary analyses performed, this observation must be interpreted with caution, and further testing should be performed in this immature population.

In summary, we found no significant difference in the primary outcome of death or bronchopulmonary dysplasia between infants randomly assigned to early CPAP and those assigned to early surfactant treatment. In secondary analyses, the CPAP strategy, as compared with early surfactant treatment, resulted in a lower rate of intubation (both in the delivery room and in the NICU), a reduced rate of postnatal corticosteroid use, and a shorter duration of ventilation without an increased risk of any adverse neonatal outcome. These data support consideration of CPAP as an alternative to routine intubation and surfactant administration in preterm infants.

Supported by grants (U10 HD21364, U10 HD21373, U10 HD21385, U10 HD21397, U10 HD27851, U10 HD27853, U10 HD27856, U10 HD27880, U10 HD27871, U10 HD27904, U10 HD34216, U10 HD36790, U10 HD40461, U10 HD40492, U10 HD40498, U10 HD40521, U10 HD40689, U10 HD53089, U10 HD53109, U10 HD53119, U10 HD53124) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, cofunding from the National Heart, Lung, and Blood Institute, and grants (M01 RR30, M01 RR32, M01 RR39, M01 RR44, M01 RR54, M01 RR59, M01 RR64, M01 RR70, M01 RR80, M01 RR125, M01 RR633, M01 RR750, M01 RR997, M01 RR6022, M01 RR7122, M01 RR8084, M01 RR16587, U11 RR25008, U11 RR24139, U11 RR24979, U11 RR25744) from the National Institutes of Health.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank our medical and nursing colleagues and the infants and their parents who agreed to take part in this study.

The New England Journal of Medicine

APPENDIX


The following are the authors’ affiliations: the Division of Neonatology, University of California at San Diego, San Diego (N.N.F., W.R.); the Division of Neonatology, University of Alabama at Birmingham, Birmingham (W.A.C., N.A.); the Department of Pediatrics, Rainbow Babies & Children’s Hospital, Case Western Reserve University, Cleveland (L.C.W., N.S.N.); Statistics and Epidemiology Unit, RTI International, Research Triangle Park (M.G.G., W.K.P.), the Department of Pediatrics, Duke University, Durham (C.M.C.), and Wake Forest University School of Medicine, Winston-Salem (T.M.O.) — all in North Carolina; the Department of Pediatrics, Women and Infants Hospital, Providence, RI (A.R.L.); the Department of Pediatrics, Division of Neonatology, University of Utah School of Medicine, Salt Lake City (B.A.Y., R.G.F.); Statistics and Epidemiology Unit, RTI International, Rockville (A.D.), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda (R.D.H.) — both in Maryland; the Department of Pediatrics, University of Cincinnati, Cincinnati (E.F.D., V.N.); the Department of Pediatrics, Division of Newborn Medicine, Floating Hospital for Children, Tufts Medical Center, Boston (I.D.F.); the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas (P.I.S.); the Department of Pediatrics, Emory University School of Medicine, and Children’s Healthcare of Atlanta — both in Atlanta (S.B.); the Department of Pediatrics, University of Texas Medical School at Houston, Houston (K.A.K.); University of Rochester School of Medicine and Dentistry, Rochester, NY (N.L.); the Department of Pediatrics, Indiana University School of Medicine, Indianapolis (B.B.P.); the Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA (K.P.Y.M.); the Department of Pediatrics, Wayne State University, Detroit (B.G.S.); University of Miami Miller School of Medicine, Miami (S.D.); the Department of Pediatrics, University of Iowa, Iowa City (E.F.B.); the Department of Pediatrics, Yale University School of Medicine, New Haven, CT (V.B.); and the University of New Mexico Health Sciences Center, Albuquerque (K.L.W.).

The following investigators, in addition to those listed as authors, participated in this study: Neonatal Research Network Steering Committee Chairs: A.H. Jobe (University of Cincinnati, Cincinnati [2003–2006]), M.S. Caplan (University of Chicago, Pritzker School of Medicine, Chicago [2006–present]); Alpert Medical School of Brown University and Women and Infants Hospital — both in Providence, RI; W. Oh, A.M.
Hensman, D., Gingras, S., Barnett, S., Lillie, K., Francis, D., Andrews, K., & Agnela; Case Western Reserve University and Rainbow Babies and Children's Hospital — both in Cleveland: A.A. Fanaroff, B.S. Siner, University of Cincinnati Children's Hospital Medical Center, University of Cincinnati Hospital, and Good Samaritan Hospital — all in Cincinnati: K. Schiabler, B. Bridges, B. Alexander, C. Grisby, M.W. Mersmann, H.L. Minecy, J. Hessling; Duke University School of Medicine University Hospital, Alhambra Regional Medical Center, and Durham Regional Hospital — all in Durham, NC: R.N. Goldberg, K.J. Auten, K.A. Fisher, K.A. Foy, G. Swayne; Emory University, Children's Healthcare of Atlanta, Grady Memorial Hospital, and Emory Crawford Long Hospital — all in Atlanta: B.J. Stoll, A. Piazza, D.P. Carlton, E.C. Hale; Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD: S.W. Archer, Indiana University, Indiana University Hospital, Methodist Hospital, Riley Hospital for Children, and Wishard Health Services — all in Indianapolis: J.A. Lemons, F. Hamer, D.E. Herron, L.C. Miller, L.D. Wilson; — all in Indianapolis: S.W. Archer; B.J. Stoll, A. Piazza, D.P. Carlton, E.C. Hale; — both in San Diego: A.A. Fanaroff, B.S. Siner, University Hospital, Alhambra Regional Medical Center, and Durham Regional Hospital — all in San Diego: A.A. Fanaroff, B.S. Siner; — both in Hartford: M. Cunningham, S.S. Cosby, V.A. Phillips; University of California at San Diego Medical Center and Sharp Mary Birch Hospital for Women — both in San Diego: M.R. Rasmusson, P.K. Wozniak, K. Arnell, R. Bridge, C. Demetrio, J. Allen, A. Guzman, G. Hensley, M.H. Lepps, M. Martin, N.A. Miller, A. Solls, D.M. Vasil, K. Wilder; University of Texas Health Science Center at Houston Medical School and Children's Hospital of Houston — both in Houston: A. Das (ex officio) RTI International, Rockville, MD; W.K. Poole (ex officio), RTI International, Bethesda, MD; C.A. Gleason (chair), University of Washington, Seattle; M.C. Allen, Johns Hopkins University School of Medicine, Baltimore; S.I. Shankaran, R. Bara, E. Billian, M. Johnson, Yal University and Yale–New Haven Children's Hospital, New Haven, and Bridgeport Hospital, Connecticut: R.A. Ehrenkranz, H.C. Jacobs, P. Cervone, P. Gettner, M. Konstantino, J. Poulsen, J. Taft; Data and Safety Monitoring Committee — G. Avery (chair), Children’s National Medical Center, Washington, DC; C.A. Gleason (chair), University of Washington, Seattle; M.C. Allen, Johns Hopkins University School of Medicine, Baltimore; S.I. Shankaran, University of North Carolina, Chapel Hill; C.J. Biaisied, D.B. Gail, C. Hunt, National Heart, Lung, and Blood Institute, Bethesda, MD; R.J. Boyle, University of Virginia Health System, Charlottesville; T. Clemons, EMMES Corporation, Rockville, MD; M.E. D’Alton, Columbia University, New York; A. Das (ex officio) RTI International, Rockville, MD; W.K. Poole (ex officio), RTI International, Research Triangle Park, NC; M. Kessler, Georgetown University Hospital, Washington, DC; C.K. Redmond, University of Pittsburgh, Pittsburgh; M.G. Ross, UCLA School of Medicine and Public Health, Los Angeles; M.A. Thomson, Hammersmith Hospital, London; S.J. Weinar, George Washington University, Washington, DC; M. Willinger (ex officio), Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD; Retinopathy of Prematurity Adjudication Committee — G.D. Markowitz, University of Rochester, Rochester, NY; A.K. Hutchinson, Emory University, Atlanta; D.K. Wallace, S.E. Freedman, Duke University, Durham, NC.

REFERENCES


Copyright © 2010 Massachusetts Medical Society.